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Tumors of the hepatobiliary system
and the pancreas
Metastases are the most common malignant tumors
affecting the liver, occurring 20 times more often than
primary carcinoma. The most common primaries
producing liver metastases are colorectal, gastric,
pancreatic, lung and breast carcinoma. Ninety percent
of malignant primary liver tumors are tumors from
epithelial origin: hepatocellular carcinoma (HCC) and
cholangiocarcinoma. Gallbladder carcinoma is uncom-
mon and is associated with cholelithiasis in 75% of the
cases. These tumors are insidious, not suspected clini-
cally, and often discovered at surgery or incidentally in
the surgical specimen.
Pancreatic carcinomas usually arise from the
pancreatic ducts and are the third most common
malignant tumor of the gastrointestinal tract and the
fifth leading cause of cancer-related mortality. Most
tumors arise in the head of the pancreas, and patients
present with bile duct obstruction, pain and jaundice.
Carcinoma of the ampulla of Vater may be difficult to
differentiate from those arising from the head of the
pancreas. Acinar cell carcinomas comprise no more
than 1%–2% of all pancreatic cancer, and the prog-
nosis is as poor as for ductal cell carcinoma. Cystic
neoplasms can arise in the pancreas and differentiation
of benign from malignant is critical. Islet cell tumors
and other endocrine tumors make up a small fraction
of all pancreatic neoplasms and are most often located
in the body and tail of the pancreas. They are
usually slow-growing tumors and are associated with
endocrine abnormalities.
Methods of diagnosis
The diagnostic issues include early detection of these
tumors, differentiation of malignant tumors from
benign tumors (lesion characterization), staging for
resection that include lesion localization, evaluation of
proximity to vessels, invasion of adjacent structures,
metastasis to regional lymph nodes and distant sites,
and assessment of therapeutic response.
Various imaging modalities are available to achieve
these goals including ultrasound (US), computed
tomography (CT), magnetic resonance imaging
(MRI), and functional imaging using radiophar-
maceuticals (Nuclear Medicine). Tomographic
imaging for functional radioisotopic studies can be
performed using single photon emission tomography
technique (SPECT) if the radiopharmaceutical is a
single photon emitter, and positron emission tomog-
raphy technique (PET) if the radiopharmaceutical
is a positron emitter. Some of these goals are better
achieved with the high resolution of anatomical
imaging techniques and others with molecular imaging
using PET.
The rapid advances in imaging technologies are a
challenge for both radiologists and clinicians who must
integrate these technologies for optimal patient care
and outcomes at minimal cost. Since the early 1990s,
numerous technological improvements have occurred
in the field of radiological imaging. These include: (1)
multislice spiral computed tomography (CT) which
permits fast acquisition of CT angiographic images
and multiphase enhancement techniques; and (2) PET
using 18F-fluorodeoxyglucose (FDG) as a radiophar-
maceutical that provides the capability for imaging
tumor metabolism.
Some of these tumors are associated with elevated
serum levels of tumor markers that can be helpful for
the diagnosis and surveillance of these patients, such
as serum levels of carcinoembryonic antigen (CEA) for
patients with colorectal carcinoma, alpha-fetoprotein
(AFP) for screening patients at risk for hepatocellular
Correspondence: Dominique Delbeke, MD, PhD, Department of Radiology and Radiological Sciences, Vanderbilt University Medical Center, 21st Avenue
South & Garland, Nashville, TN 37232-2675, USA. Tel:+1-615-343-8516. Fax:+1-615-343-6531. E-mail: Dominique.delbeke@vanderbilt.edu
HPB, 2005; 7: 166–179
ISSN 1365-182X print/ISSN 1477-2574 online # 2005 Taylor & Francis Group Ltd
DOI: 10.1060/13651820510028909
carcinoma (HCC), and Ca 19-9 for surveillance of
patients with pancreatic carcinoma, as well as various
peptides for islet cell neoplasms.
Conventional imaging modalities
Transabdominal US is well established as a valuable
screening technique that is inexpensive, portable, sen-
sitive for evaluating bile duct dilatation, the pancreas,
and can detect hepatic lesions as small as 1 cm. It can
also provide guidance for biopsy and drainage proce-
dures. Its limitations include poor sensitivity (50%)
for detection of small hepatic lesions and regional
lymphadenopathy compared to CT and MRI.
Endoscopic ultrasound is a promising new technique
for the evaluation of the extrahepatic bile ducts and
pancreatic ducts. It is sensitive in the detection cho-
ledocholithiasis and pancreatic masses. However, it
is highly operator-dependent, and requires sedation.
CT remains the first choice for a screening abdom-
inal examination at many institutions. CT and MRI for
hepatic imaging are based on the dual perfusion of the
liver: 80% of the blood flow to normal liver paren-
chyma is derived from the portal vein, whereas nearly
all of the blood flow to hepatic neoplasms is derived
from the hepatic artery. Therefore some lesions are
better seen at different times after intravenous contrast
injection. Typically, hypervascular tumors and metas-
tases (HCC, metastases of carcinoid carcinoma, islet
cell tumor, malignant pheochromocytoma, renal cell
carcinoma, sarcoma,melanoma, and breast carcinoma)
may be best seen during the arterial phase of en-
hancement, or before contrast is administered; whereas
hypovascular metastases (colorectal carcinoma, and
most metastases of other primaries) are best seen
during the portal venous phase of enhancement [1].
After invasive arterial catheterization, contrast
material can also be injected into the superior
mesenteric artery, which increases the sensitivity
for detection of small hepatic lesions, but decreases the
specificity because of non-specific perfusion defects.
This technique of CT portography is invasive and
more expensive (approximately eight times that of
CT), but has the potential to detect HCC less than
1 cm in diameter.
MRI imaging is certainly as sensitive as CT for
detection of focal hepatic lesions, but it too is inferior to
CT portography. A multitude of pulse sequences have
been developed to characterize lesions. Gadolinium
chelate contrast agents are used like the intravenous
CT contrast agents, rapidly leaving the vascular space
and reaching equilibrium throughout the extracellular
fluid compartment after about 3 minutes [2]. MR
cholangiopancreatography (MRCP) permits visuali-
zation of the biliary tree non-invasively without the
administration of contrast agents [3]. Using a heavily
T2-weighted pulse sequence, solid organs and moving
fluid have a low signal, whereas relatively stagnant
fluid (such as bile) has a high signal intensity, resulting
in the biliary tract appearing as a bright well-defined
structure. Although MRCP does not provide the re-
solution of percutaneous transhepatic cholangiography
(PTC) or endoscopic retrograde cholangiopancreato-
graphy (ERCP), it is able to clearly demonstrate intra-
luminal filling defects and luminal narrowing. MRCP
provides invaluable information in both benign and
malignant biliary tract disease.
Cholangiopancreatography via PTC or ERCP is an
invasive technique but remains the procedure of choice
for high-resolution assessment of the biliary tree anat-
omy. ERCP is performed by endoscopic cannulation
of anatomic tracts and is therefore less invasive than
PTC, which requires passage of a needle through the
liver parenchyma. Contrast material is then injected
directly into the biliary tree. Both techniques offer the
advantage of allowing interventional procedures such
as stent placement in the same setting as the imaging
procedure. PTC demonstrates the intrahepatic ducts
better than ERCP, which better depicts the extra-
hepatic ducts.
Functional imaging with conventional radiophar-
maceuticals can help to characterize lesions. 99mTc-
labeled red blood cells are a tracer of the blood pool
and are highly accurate in differentiating cavernous
hemangiomas from other lesions. 99mTc-sulfur colloid
accumulation in hepatic Kupffer cells allows char-
acterization of focal nodular hyperplasia. 131I- or 123I-
metaiodobenzylguanidine (MIBG), which localizes
through the norepinephrine reuptake mechanism into
the catecholamine storage vesicles, can be used to
image neuroendocrine tumors and their metastases.
111In-octreotide is a somatostatin analog that accu-
mulates in a variety of neuroendocrine tumors
expressing somatostatin receptors, but may also help
characterize other pathologic processes such as
lymphoma, sarcoidosis, and autoimmune diseases.
67Gallium, 201thallium, 99mTc-isonitriles (MIBI), and
radiolabeled monoclonal antibodies are poor imaging
agents for hepatic lesions due to physiological high liver
background activity.
In summary, triple phase CT functions as the stan-
dard imaging modality for the detection and character-
ization of hepatic lesions, whereas US, MRI, MRCP,
and ERCP/PTC provide complementary techniques
for further characterization of lesions in specific cir-
cumstances. Conventional radiopharmaceuticals with
or without SPECT may contribute as well but the
development and proliferation of PET may yet provide
unprecedented utility in the evaluation of these
patients.
Positron emission tomography
Molecular imaging using positron imaging is unique in
that positron emitters allow labeling of radiophar-
maceuticals that closely mimic endogenous molecules,
and there are continuing efforts to develop new
biological tracers. 18Fluorodeoxyglucose (FDG) PET,
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allowing evaluation of glucose metabolism, is the
radiopharmaceutical most widely used with the PET
technology and that has been approved by the
Health Care Financing Administration (HCFA) for
reimbursement by Medicare in the evaluation of
patients with various body tumors.
Radiopharmaceuticals for molecular
imaging with PET
18F-fluorodeoxyglucose (FDG)
Because of its ability to demonstrate glucose metabo-
lism and its longer, more practical half-life (110 min)
as compared to other short-lived positron emitters,
FDG is the most frequently used tracer for clinical ap-
plications. Multiple indications for molecular imaging
using FDG are now well accepted in the fields of
neurology, cardiology, and oncology [4].
Although variations in uptake are known to exist
among tumor types, elevated uptake of FDG has been
demonstrated in most primary malignant tumors [5].
This is due to the expression of increased numbers of
glucose transporter proteins and increased intracellular
enzyme levels of hexokinase and phosphofructokinase,
among others, which promote glycolysis [6–9]. FDG
PET imaging can be used to exploit the metabolic
differences between benign and malignant cells for
imaging purposes [10,11].
Improvements in the distribution of FDG by
commercial companies and the widespread oncologic
applications, including differentiation of benign from
malignant lesions, staging malignant lesions, detection
of malignant recurrence, and monitoring therapy, have
contributed to the establishment of the PET technol-
ogy in many medical centers in the United States,
Europe and progressively throughout the world. At
present, the major indications for FDG PET imaging is
staging and restaging of malignant tumors leading
to detection of unsuspected metastases in 25%–30%
of the patients and major changes in therapy. Because
of the limitations of FDG related to variations of
physiological uptake and overlap of uptake between
inflammatory and malignant lesions, other PET radio-
pharmaceuticals have been investigated for clinical use.
Potential new PET tracers for clinical use
Besides evaluation of glucose metabolism with FDG,
PET can assess various other biologic parameters such
as perfusion, metabolism of other compounds, hypoxia
and receptor expression. Some of these radiopharma-
ceuticals are labeled with positron emitters that have
a short half-life, such as 15O (T1/2=2 min), 13N (T1/
2=10 min), and 11C (T1/2=20 min). The short half-
life of these radioisotopes prevents any timely distri-
bution of the radiopharmaceuticals labeled with them
and therefore their use is restricted to institutions that
have a cyclotron and associated laboratories and
personnel on-site.
Tracer of bone metabolism
18F-fluoride was first described as a skeletal imaging
agent in the 1960s but then was replaced by the 99mTc-
labelled diphosphonate radiopharmaceuticals [12].
With the widespread applications of FDG PET in
oncology, PET imaging systems are becoming more
widely available, and there is a renewed interest in 18F-
fluoride. Although the mechanism of uptake for
18F-fluoride is similar to that for other bone-imaging
radiopharmaceuticals [13], the spatial resolution of
the PET technology is superior to that of both planar
and SPECT imaging using the 99mTc-radiopharma-
ceuticals. Because of the better spatial resolution
and routine acquisition of tomographic images, 18F-
fluoride PET imaging offers potential advantages
over conventional bone scintigraphy in detecting
metastases.
Tracers of DNA synthesis
The rate of DNA synthesis can be assessed using
11C-thymidine or 18F-fluorothymidine (FLT) [14].
Thymidine is a DNA precursor and allows direct
assessment of tumor proliferation. In the early nineties,
Higashi et al. [15] demonstrated that uptake in vitro
correlates with the tumor proliferative rate. Compared
to FDG, FLT uptake is lower but with a significant
linear correlation [16]. The high physiologic uptake
in the liver and bone marrow is a limitation for detec-
tion of metastases in these organs. A report of 17
patients with colorectal cancer concludes that the
high physiologic liver background limits detection of
hepatic metastases, so it is unlikely that FLT will play
a role in the evaluation of patients with colorectal
carcinoma [17].
Tracers of amino-acid transport and protein metabolism
Assessment of amino acid transport and protein
metabolism is possible with 11C-methionine and 18F-
tyrosine. 11C-methionine is used more commonly in
Europe than in the United States and has some
advantages over FDG for evaluation of brain tumors,
for example, because of the low physiologic back-
ground uptake in the cortex. Little data is available for
evaluation of gastrointestinal tumors with tracers of
amino-acid transport and protein metabolism.
Tracers of membrane lipid synthesis
11C-acetate, 11C-choline and 18F-fluorocholine
[18,19] are markers of membrane lipid synthesis
and are promising PET radiopharmaceuticals for
evaluation of some malignancies for which FDG has
limitations such as prostate carcinoma. 11C-acetate
is also a promising tracer for imaging HCC as de-
scribed in the section below. Tumor cells incorporate
acetate preferentially into lipids rather than into
amino acids or CO2 as a necessary condition for cell
proliferation [20].
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Tracers for receptor imaging
In the field of neurology, neuroreceptor imaging
has been investigated extensively. Various PET radio-
pharmaceuticals have been developed for dopamine-,
serotonin- and benzodiazepine-receptor imaging.
Some of these tracers for receptor imaging may have a
role for detection of neuroendocrine tumors.
Instrumentation formolecular imagingwithPET
The clinical utility of FDG imaging was first estab-
lished using dedicated PET tomographs equipped with
multiple rings of bismuth germanate oxide (BGO) de-
tectors, but a spectrum of equipment is now available
for positron imaging including gamma camera-based
PET at the low end of the spectrum and dedicated PET
tomographs equipped with newer detector materials.
The advantages and limitations of each of these
systems are beyond the scope of this review [21].
Anatomical and functional imaging are complementary
Although numerous studies have shown that the
sensitivity and specificity of FDG imaging is superior
to that of CT in many clinical settings, the inability of
FDG imaging to provide accurate anatomical locali-
zation remains a significant impairment in maximizing
its clinical utility. Because FDG is a tracer of glucose
metabolism, its distribution is not limited to malignant
tissue. To avoid misinterpretations, the interpreter
must be familiar with the normal pattern and physio-
logic variations of FDG distribution and with clinical
data relevant to the patient [22,23]. It is also important
to standardize the environment of the patient during
the uptake period so as to limit physiologic variations
of FDG uptake, (e.g., in activated muscular tissue).
The problem of precise anatomical localization of the
foci of abnormal uptake and differentiation of physio-
logic from pathologic foci of uptake is compounded
by the lower resolution and increased noise in the
images of many of the systems at the low end of the
spectrum and the hybrid gamma camera-based
systems.
The limitations of anatomical imaging with CT and
MRI are related to size criteria for differentiation of
benign from malignant lymph nodes, difficulty differ-
entiating post-therapy changes from tumor recurrence,
and difficulty differentiating non-opacified loops of
bowel from metastases in the abdomen and pelvis.
Close correlation of FDG studies with conventional
CT scans helps to minimize these difficulties. In prac-
tice for the past ten years, interpretation has been
accomplished by visually comparing corresponding
FDG and CT images. The interpreting physician
visually integrates the two image sets in order to pre-
cisely locate a region of increased FDG uptake on the
CT scan. To aid in image interpretation, computer soft-
ware has been developed to co-register the FDG PET
emission scans with the high-resolution anatomical
maps provided by CT [24]. These methods offer
acceptable fusion images for the brain that is sur-
rounded by a rigid structure, the skull. For the body,
co-registration of two image sets often obtained at
different points in time is technically more difficult.
Identical positioning of the patient on the imaging
table is critical. Shifting internal organ movement and
peristalsis compound the problem.
Another approach that has gained wider acceptance
recently is the hardware approach to image fusion
using multimodality imaging with an integrated PET/
CT imaging system [25].
Integrated PET/CT systems
The recent development of integrated PET/CT sys-
tems provides CT and FDG PET images obtained in a
single imaging setting, allowing optimal co-registration
of images. With these integrated systems, a diagnostic
CT scan and a PET scan can be acquired sequentially
with the patient lying on the imaging table and simply
being translated between the two systems. Accurate
calibration of the position of the imaging table and
the use of common parameters in data acquisition and
image reconstruction permit the fusion of images of
anatomy and metabolism from the same region of the
body that are registered in space and only slightly offset
in time. The fusion images provided by these systems
allow the most accurate interpretation of both CT and
FDG PET studies. Because of the high photon flux of
X-rays, CT attenuation maps from these integrated
PET/CT systems also allow for optimal attenuation
correction of the PET images.
Clinical impact of integrated PET/CT images
From the diagnostic point of view, the CT obtained for
attenuation maps can also be used for precise locali-
zation of the foci of uptake with the help of the fusion
of anatomical and molecular images. Published data
regarding the incremental value of integrated PET/CT
images compared to PET alone, or PET correlated
with a CT obtained at a different time, are limited but
conclude the following: (1) Improvement of lesion
detection on both CT and FDG PET images; (2)
Improvement of the localization of foci of FDG uptake
resulting in better differentiation of physiologic from
pathologic uptake; and (3) Precise localization of the
malignant foci, for example in the skeleton versus soft
tissue, or liver versus adjacent bowel or node. PET/CT
fusion images affect the clinical management by
guiding further procedures, excluding the need of
further procedures, and changing both inter- and intra-
modality therapy [26]. For example, precise localiza-
tion of metastatic lymph nodes could result in a less
invasive and more efficient surgical procedure. PET/
CT fusion images have the potential to provide
important information to guide the biopsy of a mass to
more metabolically active regions of the tumor and to
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provide better maps, than CT alone, to modulate field
and dose of radiation therapy [27].
Concurrent PET/CT imaging with an integrated
system may be especially important in the abdomen
and pelvis [28]. PET images alone may be difficult to
interpret owing to the absence of anatomical land-
marks (other than the kidneys and bladder), and to
the presence of non-specific uptake in the stomach,
small bowel and colon, and urinary excretion of FDG.
If possible, images of the abdomen and pelvis should be
obtained with the arms elevated to avoid artifacts due
to motion and to beam hardening artifacts on the CT
transmission images. Concurrent PET/CT imaging is
helpful for differentiating focal retention of urine in the
ureter, for example, versus an FDG-avid lymph node.
A review of PET/CT for gastrointestinal tumors has
been published recently [29]. Some data comparing
PET/CT versus PET alone are available for patients
with colorectal carcinoma and are described in the
section below.
FDG PET for evaluation of colorectal carcinoma
About 14,000 patients per year with colorectal
carcinoma present with isolated liver metastases as their
first recurrence, and about 20% of these patients die
with metastases exclusively to the liver [30]. Hepatic
resection is the only curative therapy in these patients,
but it is associated with a mortality of 2%–7% and
significant morbidity [31]. Early detection and prompt
treatment of recurrences may lead to a cure in up to
25% of patients. However, the size and number of
hepatic metastases and the presence of extra-hepatic
disease adversely affect the prognosis. The poor prog-
nosis of extra-hepatic metastases is believed to be a
contraindication to hepatic resection [32]. Therefore,
accurate non-invasive detection of inoperable disease
with imaging modalities plays a pivotal role in selecting
patients who would benefit from hepatic surgery.
A meta-analysis of 11 clinical reports encompassing
577 patients determined that the sensitivity and speci-
ficity of FDG PET for detecting recurrent colorectal
cancer were 97% and 76% respectively [33]. A compre-
hensive review of the PET literature (2,244 patients
studies) has reported a weighted average for FDG PET
sensitivity and specificity of 94% and 87% respectively,
compared to 79% and 73% for CT [34]. A meta-
analysis performed to compare non-invasive imaging
methods (US, CT, MRI and FDG PET) for the
detection of hepatic metastases from colorectal, gastric
and esophageal cancers demonstrated that FDG PET
had a higher sensitivity (90%) than MRI (76%), CT
(72%) and US (55%), with an equivalent specificity of
85% [35].
In the meta-analysis of the literature, FDG PET
imaging changed the management in 29% (102/349)
of patients [33]. The comprehensive review of the PET
literature has reported a weighted average change of
management related to FDG PET findings in 32% of
915 patients [34]. Although survival is not an end point
for a diagnostic test, Strasberg et al. [36] have esti-
mated the survival of patients who underwent FDG
PET imaging in their preoperative evaluation for re-
section of hepatic metastases. The Kaplan-Meier test
estimate of the overall survival at three years was 77%
and the lower confidence limit was 60%. These per-
centages are higher than those in previously published
series (without PET) that ranged from 30% to 64%. In
the patients undergoing FDG PET imaging prior to
hepatic resection, the three-year disease-free survival
rate was 40%, again higher than that usually reported.
Figure 1 illustrates detection of extrahepatic disease
precisely localized on PET/CT in a patient with a
history of colorectal carcinoma and recently diagnosed
with hepatic metastases.
FDG PET for monitoring therapy of hepatic
metastases
Hepatic metastases can be treated with systemic
chemotherapy or regional therapy to the liver. A variety
of procedures to administer regional therapy to hepatic
metastases has been investigated including chemo-
therapy administered through the hepatic artery using
infusion pumps, selective chemoembolization, radio-
frequency ablation, cryoablation, alcohol ablation and
radiolabeled 90Y-microspheres administered via the
hepatic artery [37–40]. There are preliminary reports
suggesting that the response to chemotherapy in
patients with hepatic metastases can be predicted with
PET. Responders may be discriminated from non-
responders after four to five weeks of chemotherapy
with fluorouracil by measuring FDG uptake before
and during therapy [41]. Regional therapy to the liver
by chemoembolization can also be monitored with
FDG PET imaging [42,43]. FDG uptake decreases in
responding lesions, and the presence of residual uptake
in some lesions can help in guiding further regional
therapy. Langenhoff et al. [44] have prospectively
monitored 23 patients with liver metastases following
radiofrequency ablation and cryoablation. Three weeks
after therapy, 51/56 metastases became FDG nega-
tive, and there was no recurrence during 16 months
of follow-up; whereas among the 5/56 lesions with
persistent FDG uptake, 4/5 recurred. Data in smaller
series of patients support their findings [45,46]. Wong
et al. [47] have compared FDG PET imaging, CT
or MRI and serum levels of CEA to monitor the
therapeutic response of hepatic metastases to 90Y-glass
microspheres. They found a significant difference
between the FDG PET changes and the changes on
CT or MRI; the changes in FDG uptake correlated
better with the changes in serum levels of CEA.
In summary, preliminary data suggest that FDG
PET imaging may be able to effectively monitor the
efficacy of regional therapy to hepatic metastases, but
these data need to be confirmed in larger series of
patients.
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PET/CT versus PET for evaluation of
colorectal carcinoma
A study of 204 patients (34 with gastrointestinal
tumors), performed at Rambam Medical Center [48]
using an integrated PET/CT system, concluded that
the diagnostic accuracy of PET is improved in ap-
proximately 50% of patients. In that study, PET/CT
fusion images improved characterization of equivocal
lesions as definitely benign in 10% of sites and defi-
nitely malignant in 5% of sites. Fusion images precisely
defined the anatomic location of malignant FDG
uptake in 6% and led to retrospective lesion detection
on PET or CT in 8%. The results of fusion PET/CT
images had an impact on the management of 14%
(28/204) of patients, 7/28 patients with a change of
management had colorectal cancer, representing 20%
(7/34) of patients with gastrointestinal tumors. The
Figure 1. A 57-year-old male with a history of colon carcinoma and recently diagnosed hepatic metastases underwent a PET/CT study for
restaging. FDG PET maximum intensity projection (MIP) image demonstrated: (1) Two foci of FDG uptake in the liver consistent with the
known hepatic metastases; (2) Two foci of FDG uptake in the lower chest to the left of the midline (arrows); (3) A focus of FDG uptake in the
pelvis (arrow). In addition, there is an artifact over the arms of the patient because they were touching the gantry and there is physiological FDG
uptake in the ascending colon, kidneys and bladder. Transaxial views through the focus of FDG uptake in the pelvis demonstrated that the focus of
uptake corresponded to a presacral lymph node indicating a metastasis (arrows). Similar images demonstrated that the foci of FDG uptake in the
chest corresponded to pleural-based soft tissue densities indicating metastases in the chest (not shown).
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changes in management in the 7 patients with color-
ectal cancer included guiding colonoscopy and biopsy
for a local recurrence (N=2), guiding biopsy to a
metastatic supraclavicular lymph node (N=1), guid-
ing surgery to localized metastatic lymph nodes (N=3)
and referral to chemotherapy (N=2). Similar conclu-
sions were found in a study of 173 patients performed
at Vanderbilt University, 24 of whom had colorectal
carcinoma [49]. A study of 45 patients with colorectal
cancer referred for FDG PET imaging using an
integrated PET/CT system concluded that PET/CT
imaging increases the accuracy and certainty of locat-
ing lesions. In their study, the frequency of equivocal
and probable lesion characterization was reduced by
50% with PET/CT compared to PET alone, the
number of definite locations was increased by 25%,
and the overall correct staging increased from 78% to
89% [50]. At the time of this writing, most institutions
acquire CT transmission images without intravenous
contrast to permit optimal attenuation correction,
but CT images without intravenous contrast do not
allow visualization of many hepatic metastases.
Therefore, although hepatic metastases are commonly
seen as FDG-avid on the PET images, no corre-
sponding lesions are seen on the non-contrasted CT
transmission images. A standard of care CT with
intravenous and oral contrast needs to be performed
if surgery is contemplated. Concurrent PET/CT
fusion images have the potential to provide better
maps than CT alone to modulate field and dose of
radiation therapy including in patients with colorectal
carcinoma [27].
FDG PET for the evaluation of
hepatocellular carcinoma
Differentiated hepatocytes normally have relatively
high glucose-6-phosphatase activity. Although experi-
mental studies have shown that glycogenesis decreases
and glycolysis increases during carcinogenesis, the
accumulation of FDG in HCC is variable due to
varying degrees of activity of the enzyme glucose-6-
phosphatase in these tumors preventing intracellular
accumulation of FDG [51–55]. FDG PET detects
only 50%–70% of HCC, but has a sensitivity greater
than 90% for all other primary (cholangiocarcinoma
and sarcoma) and metastatic tumors to the liver
[56,57]. All benign tumors, including focal nodular
hyperplasia, adenoma, and regenerating nodules,
demonstrate FDG uptake at the same level as normal
liver, except for rare granulomatous abscesses. In a
report involving one of the largest series of FDG PET
imaging for HCC (N=91), the sensitivity of FDG
PET for detection of HCC was 64% with a clinically
significant impact in 28% of patients overall [58]. A
correlation was found between the degree of FDG
uptake and the grade of malignancy [55,56]. There-
fore, FDG imaging may have a prognostic significance
in the evaluation of patients with HCC. HCC that
accumulate FDG are associated with markedly eleva-
ted alpha-fetoprotein levels [59,60]. However, FDG
PET has limited value for the differential diagnosis of
focal liver lesions in patients with chronic hepatitis C
virus infection because of the low sensitivity for
detection of HCC and the high prevalence of this
tumor in that population of patients [61].
In patients with HCC that accumulate FDG, PET
imaging is able to detect unsuspected regional and
distant metastases, as with other tumors. In a series of
23 patients with HCC who underwent FDG PET
scanning in an attempt to identify extrahepatic
metastases, 13 of the 23 patients (57%) had increased
uptake in the primary tumor and 4 of the 13 had
extrahepatic metastases demonstrated by FDG PET
images [62]. Figure 2 illustrates detection of extra-
hepatic disease precisely localized on PET/CT in a
patient just diagnosed with HCC.
Because the majority of patients with HCC have
advanced-stage tumors and/or underlying cirrhosis
with impaired hepatic reserve, surgical resection is
often not possible. Therefore, other treatment strate-
gies have been developed, including hepatic arterial
chemoembolization, systemic chemotherapy, surgical
cryoablation, ethanol ablation, radiofrequency abla-
tion, and, in selected cases, liver transplantation. In
patients treated with hepatic arterial chemoemboliza-
tion, FDG PET is more accurate than lipiodol reten-
tion on CT in predicting the presence of residual
viable tumor. The presence of residual uptake in some
lesions can help in guiding further regional therapy
[63–65].
11C-acetate for hepatocellular carcinoma
PET with 11C-acetate has been shown to be useful in
detection of HCC. Possible biochemical pathways that
lead to accumulation of 11C-acetate in tumors include:
(1) entry into the Krebs cycle from acetyl coenzyme
A (acetyl CoA) or as an intermediate metabolite;
(2) esterification to form acetyl CoA as a major
precursor in b-oxidation for fatty acid synthesis; (3)
combining with glycine in heme synthesis; and (4)
through citrate for cholesterol synthesis. Among
these possible metabolic pathways, participation in
free fatty acid synthesis is believed to be the dominant
method of incorporation into tumors. Ho et al. [66]
reported a study of 57 patients with various hepato-
biliary tumors who underwent both FDG and
11C-acetate PET imaging. For the 23 patients with
HCC, the sensitivities of FDG and 11C-acetate
imaging were 47% and 87% respectively, with a
combined sensitivity of 100%. Well-differentiated
tumors tended to be 11C-acetate-avid whereas poorly
differentiated tumors tended to be FDG-avid. Other
malignant tumors were FDG-avid but not 11C-acetate-
avid. Benign tumors, such as adenoma and heman-
gioma were not 11C-acetate-avid except for mild
uptake in FNH.
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Figure 2. A 77-year-old male with a history of cirrhosis and elevated AFP presented with a large hepatic mass. FDG PET maximum intensity
projection (MIP) image demonstrated: (1) Heterogenous FDG uptake in the large hepatic mass consistent with hepatocellular carcinoma;
(2) A focus of FDG uptake at the level of the renal hila on the midline (arrow). In addition there is physiological FDG uptake in the ascending
colon and kidneys, ureters and bladder. Transaxial views through the focus of FDG uptake in the abdomen demonstrated that the focus of
uptake corresponded to a retroperitoneal lymph node indicating a metastasis (arrows). Systematic review of the transaxial images
demonstrated another abnormal focus of FDG uptake in the chest at the right lung base corresponding to a pulmonary nodule indicating a lung
metastasis (arrow).
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FDG PET for the evaluation of
cholangiocarcinoma and
gallbladder carcinoma
There is preliminary evidence that FDG PET imaging
may be useful in the diagnosis and management of
small cholangiocarcinomas in patients with sclerosing
cholangitis [67]. Anderson et al. [68] reviewed 36
consecutive patients who underwent FDG PET for
suspected cholangiocarcinoma. Patients were divided
into group 1: nodular type (mass41 cm) (N=22) and
group 2: infiltrating type (N=14). The sensitivity for
nodular morphology was 85%, but only 18% for infil-
trating morphology. Sensitivity for metastases was 65%
with three false negative for carcinomatosis and one
false positive result in a patient with primary sclerosing
cholangitis who had acute cholangitis. Seven of 12
patients (58%) had FDG uptake along the tract of a
biliary stent. FDG PET led to a change in surgical
management in 30% of patients (11/36) because of
detection of unsuspected metastases.
Unsuspected gallbladder carcinoma is discovered
incidentally in 1% of routine cholecystectomies. At
present, the majority of cholecystectomies are
performed laparoscopically, and occult gallbladder
carcinoma found after laparoscopic cholecystectomy
has been associated with reports of gallbladder car-
cinoma seeding of laparoscopic trocar sites [69,70].
Increased FDG uptake has been demonstrated in
gallbladder carcinoma [71] and has been helpful in
identifying recurrence in the area of the incision when
CT could not differentiate scar tissue from malignant
recurrence [72]. In a study reviewing 14 patients with
gallbladder carcinoma, the sensitivity for detection of
residual gallbladder carcinoma was 78%. Sensitivity
for extrahepatic metastases was 50% in 8 patients; 6 of
these had carcinomatosis [68].
FDG PET for the evaluation of
pancreatic carcinoma
The difficulty in correctly determining a preoperative
diagnosis of pancreatic carcinoma is associated with
two types of adverse outcomes. First, less aggressive
surgeons may abort attempted resection due to a lack
of tissue diagnosis. This is borne out by the signifi-
cant rate of ‘reoperative’ pancreaticoduodenectomy
performed at major referral centers [73–75]. In a recent
review of the MD Anderson Cancer Center involving
29 patients undergoing successful pancreaticoduode-
nectomy after failure to resect at the time of initial
laparotomy, 31% did not undergo resection at the
time of the initial procedure because of the lack of
tissue confirmation of malignancy [75]. A second
type of adverse outcome generated by failure to
obtain a preoperative diagnosis occurs when more
aggressive surgeons inadvertently resect benign dis-
ease. This is particularly notable in those patients
who present with suspected malignancy without an
associated mass on CT scan, occurring in up to 55% of
patients [76].
In order to avoid these adverse outcomes, metabolic
imaging with FDG PET may be used to improve the
accuracy of the preoperative diagnosis of pancreatic
carcinoma. The summary of the literature published in
2001 reported an average sensitivity and specificity of
94% and 90% respectively [26]. Although the sensi-
tivity of CT imaging rises with increasing lesion size,
the sensitivity of FDG PET does not appear to be
affected by size, [77]. Figure 3 illustrates detection of a
pancreatic carcinoma with PET/CT in a patient with
no definite mass on CT and a non-diagnostic fine
needle biopsy. The degree of FDG uptake is reported
to have a prognostic value. Nakata et al. [78] noted a
correlation between SUV and survival in 14 patients
with pancreatic adenocarcinoma. Patients with an
SUV43.0 had a mean survival of 5 months compared
to 14 months in those with an SUV53.0. Zimny et al.
[79] performed a multivariate analysis on 52 patients
with pancreatic cancer to determine the prognostic
value of FDG PET. The median survival of 26 patients
with an SUV 46.1 was 5 months compared to 9
months for 26 patients with an SUV 56.1. The
multivariate analysis revealed that SUV and Ca 19-9
were independent predictors of prognosis.
As for other tumors, FDG imaging has not been
superior to helical CT for regional N staging, but is
more accurate than CT for M staging. In the study by
Delbeke et al. [80], metastases were diagnosed both on
CT and PET in 10/21 patients with stage IV disease,
but PET demonstrated hepatic metastases not iden-
tified or equivocal on CT and/or distant metastases
unsuspected clinically in 7 additional patients. In four
patients, neither CT nor PET imaging showed
evidence of metastases, but surgical exploration
revealed carcinomatosis in three and a small liver
metastasis in one patient. The addition of FDG PET
imaging to CT altered the surgical management in
41% of the patients: 27% by detecting CT-occult
pancreatic carcinoma and 14% by identifying unsus-
pected distant metastases, or by clarifying the benign
nature of lesions equivocal on CT. Another report of
19 patients concludes that FDG PET added important
additional information to clinicians in 50% of the
patients, resulting in a change of therapeutic procedure
[81]. This includes patients with elevated tumor
markers levels, and no findings on anatomical imaging.
Preliminary data suggest that FDG PET imaging
is useful for the assessment of tumor response to
neo-adjuvant therapy and the evaluation of possible
recurrent disease following resection [77].
Therefore, FDG PET may be particularly useful
when CT identifies an indistinct abnormality in the bed
of the resected pancreas that is difficult to differentiate
from postoperative or postradiation fibrosis, for the
evaluation of new hepatic lesions that may be too small
to biopsy, and in patients with rising tumor markers
levels and a negative conventional work-up.
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FDG PET for evaluation of islet cells and
other endocrine tumors of the pancreas
Most neuroendocrine tumors, including carcinoid,
paraganglioma, and islet cell tumors, express somato-
statin receptors (SSR) and can, therefore, be imaged
effectively with somatostatin analogs such as 111In-
octreotide. This modality has been reported to be more
sensitive than CT for defining the extent of metastatic
disease, especially in extrahepatic and extra-abdominal
sites. However, there may be significant heterogeneity
in regard to SSR expression, even in the same patient in
adjacent sites, probably related to dedifferentiation of
the tumor. Absence of SSR positivity is reported to be a
poor prognostic sign, but virtually all of these SSR-
negative neuroendocrine tumors will accumulate FDG
and can therefore be imaged with PET [82]. More
differentiated SSR-positive tumors do not reliably
accumulate significant FDG and may, therefore, be
false negative with FDG PET imaging [83]. There
is controversy in the literature about the sensitivity
of FDG imaging for detection of carcinoid tumors
[84,85], but at least in some reports, 111In-octreotide
scintigraphy is more sensitive than FDG PET imag-
ing; FDG positive/octreotide-negative tumors tend
to be less differentiated and may have a less favorable
prognosis.
Other positron emitting tracers seem to be more
promising. A serotonin precursor 5-hydroxytryptophan
(5-HTP) labeled with 11C has shown an increased
uptake in carcinoid tumors. This uptake seems to be
selective and some clinical evidence has demonstrated
that it allows the detection of more lesions with PET
than with CT or octreotide scintigraphy. Another
Figure 3. A 78-year-old female presented with abdominal pain and jaundice. An ERCP was performed and stent placed in the pancreatic duct. No
definite mass was seen on CT and a fine needle biopsy was non-diagnostic. FDG PET maximum intensity projection (MIP) image demonstrated a
focus of FDG uptake in the mid-abdomen on the midline (arrow). In addition there is physiological FDG uptake in the myocardium, colon,
kidneys and bladder. Transaxial views through the focus of FDG uptake in the mid-abdomen demonstrated that the focus of uptake corresponded
to the head of the pancreas indicating pancreatic cancer (arrows), which was proven at surgery.
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radiopharmaceutical in development for PET is 11C L-
DOPA and 18F-DOPA, which seems to be useful in
visualizing gastrointestinal neuroendocrine tumors
[86,87]. A study of 17 patients with 92 carcinoid
tumors comparing FDG PET, 18F-DOPA PET and
somatostatin-receptor scintigraphy demonstrated the
following sensitivities: 29% for FDG PET, 60% for
18F-DOPA, 57% for somatostatin-receptor scin-
tigraphy and 73% for morphologic procedures [88].
An octreotide derivative can be labeled with 64Cu
(half-life, 12.7 h; beta+, 0.653 MeV (17.4%); beta-,
0.579 MeV (39%)) and has shown potential as
a radiopharmaceutical for PET imaging and radio-
therapy. A pilot study in humans has demon-
strated that 64Cu-TETA-octreotide (where TETA is
1,4,8,11-tetraazacyclotetradecane-N,N0,N00,N000-tetra-
acetic acid) and PET can be used to detect somatos-
tatin-receptor-positive tumors in humans. The high
rate of lesion detection, sensitivity, and favorable
dosimetry and pharmacokinetics of 64Cu-TETA-OC
indicate that it may be a promising radio-
pharmaceutical for PET imaging of patients with
neuroendocrine tumors [89].
Limitations of FDG imaging
Scintigraphic tumor detectability depends on both the
size of the lesion and the degree of uptake, as well as
surrounding background uptake and intrinsic resolu-
tion of the imaging system. Small lesions may yield
false negative results which can be due to partial
volume averaging, leading to underestimation of the
uptake in small lesions (of less than twice the resolution
of the imaging system, for example small ampullary
carcinoma, cholangiocarcinoma of the infiltrating
type and military carcinomatosis) or in necrotic lesions
with a thin viable rim, falsely classifying these lesions as
benign instead of malignant. The sensitivity of FDG
PET for detection of mucinous adenocarcinoma is
lower than for non-mucinous adenocarcinoma (41%–
58% versus 92%), probably because of the relative
hypocellularity of these tumors [90]. Other false nega-
tives include differentiated neuroendocrine tumors
and HCC. The high incidence of glucose intolerance
and diabetes exhibited by patients with pancreatic
pathology represents a potential limitation of this
modality in the diagnosis of pancreatic cancer, because
elevated serum glucose levels result in decreased FDG
uptake in tumors due to competitive inhibition. Low
SUV values and false negative FDG PET scans have
been noted in hyperglycemic patients.
In view of the known high uptake of FDG by acti-
vated macrophages, neutrophils, fibroblasts and gran-
ulation tissue, it is not surprising that inflammatory
tissue demonstrates FDG activity. Mild to moderate
FDG activity seen early after radiation therapy, along
recent incisions, infected incisions, biopsy sites, drai-
nage tubing and catheters, as well as colostomy sites,
can lead to errors in interpretation if the history is not
known. Some inflammatory lesions, especially granu-
lomatous ones, may be markedly FDG-avid and can be
mistaken for malignancies; this includes inflammatory
bowel disease, abscesses, acute cholangitis, acute
cholecystitis, acute pancreatitis, and chronic active
pancreatitis with or without abscess formation. False
positive studies are frequent in patients with elevated
C-reactive protein and/or acute pancreatitis with a
specificity as low as 50% [91,92]. Therefore, screening
for C-reactive protein has been recommended. Other
lesions with false positive images that have been
reported are serous cystadenoma and retroperitoneal
fibrosis.
FDG uptake normally present in the gastrointestinal
tract can occasionally be difficult to differentiate from
a malignant lesion. Incidental colonic FDG uptake in
27 patients without colorectal carcinoma has been
correlated with colonoscopic and/or histolopathologic
findings [93]. Diffuse uptake in eight patients was
normal and associated with a normal colonoscopy.
Segmental uptake was due to colitis in 5/6 patients.
Focal uptake in seven patients was associated with
benign adenomas. The clinical history, physical exam-
ination, pattern of uptake and correlation with anatomy
as seen on the CT images are more helpful in avoiding
false positive interpretations than semiquantitative
evaluation by SUV.
Summary
Evaluation of patients with known or suspected
recurrent colorectal carcinoma is now an accepted
indication for FDG PET imaging. FDG PET does not
replace imaging modalities such as CT for preoperative
anatomic evaluation, but is indicated as the initial test
for diagnosis and staging of recurrence, and for pre-
operative staging (N and M) of known recurrence that
is considered to be resectable. FDG PET imaging is
valuable for differentiation of post-treatment changes
from recurrent tumor, differentiation of benign from
malignant lesions (indeterminate lymph nodes, hepatic
and pulmonary lesions) and evaluation of patients
with rising tumor markers in the absence of a known
source. FDG PET has an impact on the treatment of
25%–30% of patients. Addition of FDG PET to the
evaluation of these patients reduces overall treatment
costs by accurately identifying patients who will and
will not benefit from surgical procedures.
FDG PET imaging seems promising for monitoring
patient response to therapy, including regional therapy
to the liver, but larger studies are necessary.
FDG PET imaging appears helpful to differentiate
malignant from benign hepatic lesions, with the excep-
tion of false negative HCC, false negative infiltrating
cholangiocarcinoma, and false positive inflammatory
lesions. It is not helpful to identify HCC in patients
with cirrhosis and regenerating nodules. In patients
with hepatic primary malignant tumors trapping FDG,
FDG PET imaging does identify unexpected distant
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metastases (although military carcinomatosis is often
false negative) and can help in monitoring therapy.
FDG PET imaging is especially helpful for the pre-
operative diagnosis of pancreatic carcinoma in patients
with suspected pancreatic cancer in whom CT fails to
identify a discrete tumor mass or in whom FNAs are
non-diagnostic. By providing preoperative document-
ation of pancreatic malignancy in these patients,
laparotomy may be undertaken with a curative intent,
and the risk of aborting resection due to diagnostic
uncertainty is minimized. FDG PET imaging is also
useful for M staging and restaging by detecting
CT-occult metastatic disease, and allowing non-
therapeutic resection to be avoided altogether in this
group of patients. As is true with other neoplasms,
FDG PET can differentiate post-therapy changes
from recurrence and holds promise for monitoring
neo-adjuvant chemoradiation therapy.
FDG PET imaging is complementary to morpho-
logical imaging with CT; therefore, integrated PET/
CT imaging provides optimal images for interpreta-
tion. The diagnostic implications of integrated PET/
CT imaging include improved detection of lesions on
both the CT and FDG PET images, better differ-
entiation of physiologic from pathologic foci of metab-
olism, and better localization of the pathologic foci.
This new powerful technology provides more accurate
interpretation of both CT and FDG PET images and
therefore more optimal patient care. PET/CT fusion
images affect the clinical management by guiding
further procedures (biopsy, surgery, radiation ther-
apy), excluding the need for additional procedures,
and changing both inter- and intra-modality therapy.
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